Affinity Asset Advisors

Latest statistics and disclosures from Affinity Asset Advisors's latest quarterly 13F-HR filing:

Tip: Access up to 7 years of quarterly data

Positions held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Affinity Asset Advisors

Companies in the Affinity Asset Advisors portfolio as of the March 2022 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) 54.2 $339M NEW 750k 451.64
Springworks Therapeutics (SWTX) 3.7 $23M +36% 407k 56.44
Inari Medical Ord (NARI) 3.2 $20M +76% 220k 90.64
Morphic Hldg (MORF) 3.0 $19M +16% 466k 40.15
Kura Oncology (KURA) 2.4 $15M +65% 924k 16.08
Ascendis Pharma A/s Sponsored Adr (ASND) 2.3 $14M NEW 120k 117.36
Chinook Therapeutics (KDNY) 2.2 $14M +52% 845k 16.36
Protagonist Therapeutics (PTGX) 2.0 $12M +113% 516k 23.68
Establishment Labs Holdings Ord (ESTA) 1.9 $12M +125% 175k 67.39
Travere Therapeutics Note 2.500% 9/1 (Principal) 1.8 $12M +57% 11M 1.04
Astrazeneca Sponsored Adr (AZN) 1.7 $11M NEW 160k 66.34
Zentalis Pharmaceuticals (ZNTL) 1.5 $9.6M +76% 208k 46.14
Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) 1.4 $8.6M NEW 155k 55.31
Nanostring Technologies Note 2.625% 3/0 (Principal) 1.2 $7.8M NEW 7.0M 1.11

Setup an alert

Affinity Asset Advisors will file the next quarterly 13-HR in about 3 months. Would you like to be notified?

Madrigal Pharmaceuticals (MDGL) 1.2 $7.4M +15% 75k 98.12
Arya Sciences Acquisitn Corp Class A Ord Shs (ARYE) 1.1 $6.8M 703k 9.72
Repare Therapeutics Ord (RPTX) 1.1 $6.7M +72% 469k 14.24
Pmv Pharmaceuticals Call Option (PMVP) 1.1 $6.6M NEW 317k 20.82
Nanostring Technologies (NSTG) 1.0 $6.0M NEW 172k 34.75
Vincerx Pharma Com New (VINC) 0.9 $5.5M +21% 1.4M 4.00
Rocket Pharmaceuticals (RCKT) 0.8 $4.8M +81% 300k 15.86
Bridgebio Pharma Note 2.250% 2/0 (Principal) 0.7 $4.7M NEW 10M 0.47
Bridgebio Pharma Note 2.500% 3/1 (Principal) 0.7 $4.4M 7.5M 0.58
Celldex Therapeutics Com New (CLDX) 0.7 $4.3M +25% 125k 34.06
Bellus Health Com New (BLU) 0.7 $4.1M +20% 600k 6.88
Cymabay Therapeutics (CBAY) 0.6 $4.0M +13% 1.3M 3.11
Crispr Therapeutics Namen Akt Call Option (CRSP) 0.6 $3.5M NEW 55k 62.76
Horizon Therapeutics Pub L SHS (HZNP) 0.5 $3.2M NEW 30k 105.20
Health Sciences Acq Corp 2 Ord Shs (HSAQ) 0.5 $3.0M 300k 9.91
Medicus Sciences Acquisition Cl A Shs (MSAC) 0.5 $2.9M 300k 9.78
Travere Therapeutics (TVTX) 0.4 $2.6M +100% 100k 25.77
Cerevel Therapeutics Hldng I (CERE) 0.4 $2.5M -68% 70k 35.01
Xenon Pharmaceuticals (XENE) 0.4 $2.4M -46% 80k 30.57
Nautilus Biotechnology (NAUT) 0.4 $2.4M -46% 559k 4.34
Global Blood Therapeutics In (GBT) 0.4 $2.4M NEW 70k 34.64
Relay Therapeutics Call Option (RLAY) 0.4 $2.2M NEW 75k 29.93
Aurinia Pharmaceuticals Call Option (AUPH) 0.3 $2.2M NEW 175k 12.38
Aclaris Therapeutics (ACRS) 0.3 $1.7M -75% 100k 17.24
Beam Therapeutics Call Option (BEAM) 0.3 $1.7M NEW 30k 57.30
Context Therapeutics (CNTX) 0.3 $1.7M NEW 778k 2.17
Cyclacel Pharmaceuticals (CYCC) 0.2 $1.2M 400k 3.05
Lianbio Sponsored Ads (LIAN) 0.2 $1.2M +348% 325k 3.71
Science 37 Holdings (SNCE) 0.2 $1.2M +47% 221k 5.35
Karuna Therapeutics Ord (KRTX) 0.2 $951k NEW 7.5k 126.80
Miragen Therapeutics (VRDN) 0.1 $925k NEW 50k 18.50
Athersys Put Option (ATHX) 0.1 $858k NEW 1.4M 0.61
Renovacor (RCOR) 0.1 $846k +59% 200k 4.24
Curis Com New (CRIS) 0.1 $833k -79% 350k 2.38
Celularity Com Cl A Put Option (CELU) 0.1 $697k NEW 80k 8.71
Centessa Pharmaceuticals Sponsored Ads (CNTA) 0.1 $586k -84% 65k 8.98
Calithera Biosciences (CALA) 0.1 $404k NEW 1.0M 0.40
Immatics *w Exp 07/01/202 (IMTXW) 0.1 $328k 187k 1.75
Hyperfine Com Cl A (HYPR) 0.0 $270k 76k 3.55
Blueprint Medicines (BPMC) 0.0 $127k NEW 2.0k 63.88
Renovacor *w Exp 99/99/999 (RCOR.WS) 0.0 $26k 75k 0.35
Medicus Sciences Acquisition *w Exp 02/12/202 (MSACW) 0.0 $14k 33k 0.42

Past Filings by Affinity Asset Advisors

SEC 13F filings are viewable for Affinity Asset Advisors going back to 2020